Novacyt Past Earnings Performance
Past criteria checks 0/6
Novacyt's earnings have been declining at an average annual rate of -48.1%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 23% per year.
Key information
-48.1%
Earnings growth rate
-47.6%
EPS growth rate
| Biotechs Industry Growth | 30.8% |
| Revenue growth rate | -23.0% |
| Return on equity | -53.1% |
| Net Margin | -201.3% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Novacyt S.A. (EPA:ALNOV) Not Doing Enough For Some Investors As Its Shares Slump 36%
Sep 30
Novacyt S.A. (EPA:ALNOV) Stock Catapults 39% Though Its Price And Business Still Lag The Industry
Aug 16Here's Why Novacyt (EPA:ALNOV) Must Use Its Cash Wisely
Aug 15Revenues Working Against Novacyt S.A.'s (EPA:ALNOV) Share Price
Jun 14Is Novacyt (EPA:ALNOV) In A Good Position To Deliver On Growth Plans?
Nov 28We're Keeping An Eye On Novacyt's (EPA:ALNOV) Cash Burn Rate
Jul 04Estimating The Fair Value Of Novacyt S.A. (EPA:ALNOV)
Jan 24With EPS Growth And More, Novacyt (EPA:ALNOV) Is Interesting
Mar 18With EPS Growth And More, Novacyt (EPA:ALNOV) Is Interesting
Nov 25Little Excitement Around Novacyt S.A.'s (EPA:ALNOV) Earnings As Shares Take 25% Pounding
Sep 29Novacyt's (EPA:ALNOV) Wonderful 999% Share Price Increase Shows How Capitalism Can Build Wealth
Mar 08Is Novacyt S.A.'s(EPA:ALNOV) Recent Stock Performance Tethered To Its Strong Fundamentals?
Jan 22
Calculating The Intrinsic Value Of Novacyt S.A. (EPA:ALNOV)
Dec 15We're Not Counting On Novacyt (EPA:ALNOV) To Sustain Its Statutory Profitability
Nov 19Revenue & Expenses Breakdown
How Novacyt makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 19 | -37 | 25 | 3 |
| 31 Mar 24 | 15 | -33 | 22 | 3 |
| 31 Dec 23 | 12 | -28 | 18 | 3 |
| 30 Sep 23 | 10 | -27 | 17 | 3 |
| 30 Jun 23 | 8 | -25 | 15 | 3 |
| 31 Mar 23 | 14 | -24 | 16 | 4 |
| 31 Dec 22 | 21 | -22 | 17 | 5 |
| 30 Sep 22 | 39 | -11 | 18 | 6 |
| 30 Jun 22 | 57 | 1 | 19 | 6 |
| 31 Mar 22 | 75 | -2 | 20 | 5 |
| 31 Dec 21 | 93 | -6 | 22 | 5 |
| 30 Sep 21 | 179 | 40 | 30 | 4 |
| 30 Jun 21 | 266 | 85 | 38 | 3 |
| 31 Mar 21 | 272 | 109 | 36 | 2 |
| 31 Dec 20 | 277 | 132 | 35 | 2 |
| 30 Sep 20 | 173 | 83 | 24 | 1 |
| 30 Jun 20 | 68 | 33 | 13 | 1 |
| 31 Mar 20 | 40 | 15 | 11 | 1 |
| 31 Dec 19 | 11 | -3 | 8 | 0 |
| 30 Sep 19 | 12 | -3 | 8 | 0 |
| 30 Jun 19 | 13 | -2 | 8 | 0 |
| 31 Mar 19 | 12 | -2 | 7 | 0 |
| 31 Dec 18 | 12 | -2 | 8 | 0 |
| 30 Jun 18 | 11 | -3 | 6 | 0 |
| 31 Mar 18 | 11 | -3 | 6 | 0 |
| 31 Dec 17 | 11 | -3 | 7 | 1 |
| 30 Sep 17 | 12 | -4 | 9 | 1 |
| 30 Jun 17 | 12 | -3 | 8 | 1 |
| 31 Mar 17 | 10 | -4 | 8 | 1 |
| 31 Dec 16 | 9 | -5 | 7 | 1 |
| 30 Sep 16 | 9 | -9 | 7 | 1 |
| 30 Jun 16 | 8 | -13 | 6 | 1 |
| 31 Mar 16 | 7 | -12 | 6 | 0 |
| 31 Dec 15 | 7 | -10 | 5 | 0 |
| 30 Sep 15 | 6 | -7 | 5 | 1 |
| 30 Jun 15 | 6 | -4 | 5 | 1 |
| 31 Mar 15 | 5 | -3 | 4 | 0 |
| 31 Dec 14 | 4 | -3 | 3 | 0 |
| 30 Sep 14 | 2 | -2 | 2 | 1 |
| 30 Jun 14 | 1 | -1 | 1 | 0 |
| 31 Mar 14 | 1 | -1 | 1 | 0 |
| 31 Dec 13 | 1 | -1 | 1 | 0 |
Quality Earnings: ALNOV is currently unprofitable.
Growing Profit Margin: ALNOV is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ALNOV is unprofitable, and losses have increased over the past 5 years at a rate of 48.1% per year.
Accelerating Growth: Unable to compare ALNOV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALNOV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).
Return on Equity
High ROE: ALNOV has a negative Return on Equity (-53.06%), as it is currently unprofitable.